About: Reduced Duration of Postchikungunya Musculoskeletal Pain in Rheumatological Patients Treated with Biologicals

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Reduced Duration of Postchikungunya Musculoskeletal Pain in Rheumatological Patients Treated with Biologicals Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Reduced Duration of Postchikungunya Musculoskeletal Pain in Rheumatological Patients Treated with Biologicals
Creator	Duarte, Angela França, Rafael Lima, Anton Lopes, Fabiana Marques, Claudia Marques, Gabriel Monteiro, Janaína Valadares, Maria De Brito, Carlos De Brito, Marina
Source	Medline; PMC
abstract	Chikungunya fever (CHIK) has caused important epidemic outbreaks in the Americas, with musculoskeletal involvement being the main manifestation, causing chronic symptoms in half of the affected patients. This study was performed to evaluate the clinical course of the infection in 168 patients with autoimmune inflammatory disease using biological disease-modifying antirheumatic drugs (bDMARDs), comparing this group with 56 household controls. Anti-CHIKV IgG serology was positive in 42 (25%) of the patients in the bDMARD group and in 15 (27%) of the controls (p=0.79). Of those with positive serology, 32 (76%) and 14 (93%) were symptomatic among subjects in the bDMARD and control groups, respectively (p=0.87). Persistence of musculoskeletal symptoms for more than three months occurred in 64% of the patients in the control group and only in 28% in the bDMARD group (p=0.021), maintaining a statistically significant difference only for users of anti-TNF. This study found that patients affected by chikungunya fever using bDMARDs did not present severe forms or complications in the acute phase of the disease, and patients using anti-TNF biologicals had a lower frequency of chronic joint symptoms than the household controls. This favorable outcome may be related to the cytokine blockade, with a reduction in the inflammatory response and joint damage.
has issue date	2020-07-10(xsd:dateTime)
bibo:doi	10.1155/2020/2071325
bibo:pmid	32695184
has license	cc-by
sha1sum (hex)	f30c342934d1c06634401f59efdd22503424c1b9
schema:url	https://doi.org/10.1155/2020/2071325
resource representing a document's title	Reduced Duration of Postchikungunya Musculoskeletal Pain in Rheumatological Patients Treated with Biologicals
has PubMed Central identifier	PMC7368942
has PubMed identifier	32695184
schema:publication	J Trop Med
resource representing a document's body	covid:f30c342934d1c06634401f59efdd22503424c1b9#body_text
is schema:about of	named entity 'Persistence' named entity 'positive' named entity 'patients' named entity 'patients' named entity 'joint' named entity 'anti-TNF' named entity 'serology' named entity 'patients' named entity 'inflammatory disease' named entity 'Patients' named entity 'FREQUENCY' named entity 'IMPORTANT' named entity 'patients' named entity 'positive' named entity 'Americas' named entity 'acute' named entity 'Chikungunya fever' named entity 'Musculoskeletal' named entity 'Americas' named entity 'CHIKV' named entity 'Chikungunya fever' named entity 'anti-TNF' named entity 'acute phase' named entity 'rheumatologic disease' named entity 'chronic inflammatory' named entity 'immune response' named entity 'Chikungunya fever' named entity 'inflammatory cytokines' named entity 'CHIKV' named entity 'Northeast Brazil' named entity 'chikungunya' named entity 'arthralgia' named entity 'chikungunya fever' named entity 'acute infection' named entity 'serology' named entity 'disease pattern' named entity 'virus' named entity 'FIOCRUZ' named entity 'arthritis' named entity 'mice' named entity 'evolution' named entity 'inflammation' named entity 'chikungunya' named entity 'statistically significant' named entity 'COVID-19' named entity 'joint pain' named entity 'seroprevalence' named entity 'hepatitis B virus' named entity 'rheumatologic disease' named entity '1, 2' named entity 'acute phase' named entity 'arthropathy' named entity 'disease-modifying' named entity 'Germany' named entity 'CHIKV' named entity 'control group' named entity 'CHIKV' named entity 'biological therapy' named entity 'BALB/c' named entity 'central nervous' named entity 'biologicals' named entity 'arbovirus infections' named entity 'Americas' named entity 'endemic' named entity 'arthropathy' named entity 'evolution' named entity 'acute episode' named entity 'immunomodulatory' named entity 'confidence interval' named entity 'chi-square test' named entity 'anti-TNF' named entity 'UFPE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software